Results 1 to 10 of about 65,616 (255)

HIV: Pre-exposure prophylaxis

International Journal of Preventive Medicine, 2012
Results of one study (iPrEx study) showed that a once‑daily pill containing tenofovir plus emtricitabine was safe and provided an average of 44% additional protection against HIV infection to men and transgender women who have sex with men, who were also provided with a comprehensive package of prevention services.
Ajai Kumar Singh, Ashish Singh, Deepti Singh, Manish Singh, Pratibha Singh, Abhishek Sharma   +5 more
doaj   +5 more sources

Evolving landscape of economic evaluations of HIV pre‐exposure prophylaxis and pre‐exposure prophylaxis implementation strategies: a systematic review [PDF]

Journal of the International AIDS Society
Introduction Economic evaluations of HIV pre‐exposure prophylaxis (PrEP) and associated implementation strategies guide evidence‐based policies, programmes and resource allocation.
Min Xi, Darrell H. S. Tan, Stefan D. Baral, Howsikan Kugathasan, Lisa Masucci, Becky Skidmore, Derek R. MacFadden, Kednapa Thavorn, Sharmistha Mishra   +8 more
doaj   +2 more sources

Modeling HIV Pre-Exposure Prophylaxis

Frontiers in Pharmacology, 2020
Pre-exposure prophylaxis (PrEP) has emerged as a promising strategy for preventing the transmission of HIV. Although only one formulation is currently approved for PrEP, research into both new compounds and new delivery systems for PrEP regimens offer ...
Thomas Straubinger, Katherine Kay, Robert Bies   +2 more
doaj   +3 more sources

Pre-exposure Prophylaxis: The Delivery Challenge [PDF]

Frontiers in Public Health, 2018
HIV pre-exposure prophylaxis (PrEP), despite its efficacy, has been slow in uptake throughout the world. This article discusses the operational and service delivery complexity, based on early real-world experience, with some recommendations on how this ...
Willem D. F. Venter
doaj   +3 more sources

HIV pre-exposure prophylaxis for women

Journal of Virus Eradication, 2016
Women and girls comprise nearly half of HIV-infected individuals globally and 20% of new infections in the United States, indicating an urgent need to optimise HIV prevention options in this population.
Anandi N. Sheth, Charlotte P. Rolle, Monica Gandhi   +2 more
doaj   +3 more sources

Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium

AIDS Patient Care and STDs, 2022
It remains unclear why patients discontinue HIV pre-exposure prophylaxis (PrEP) care and to what extent they remain at risk for HIV when they do. We reviewed routinely collected medical records and patient questionnaires and performed an e-mail/telephone survey to assess reasons for discontinuing PrEP care, ongoing risks for HIV ...
Marie Laga, Bart K M Jacobs, Eric Florence   +2 more
exaly   +3 more sources

Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure

Frontiers in Pharmacology, 2019
As pre-exposure prophylaxis (PrEP) effectiveness is strongly linked to adherence, we sought to determine if certain self-report measures could be used to inform objective PrEP adherence.
Jill Blumenthal, Elizabeth C. Pasipanodya, Sonia Jain, Shelly Sun, Eric Ellorin, Sheldon Morris, David J. Moore   +6 more
doaj   +3 more sources

Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina [PDF]

Cost Effectiveness and Resource Allocation
Background Some immunosuppressive disorders have shown substantially lower protection after COVID-19 vaccination against severe outcomes. Therefore, pre-exposure prophylaxis is proposed.
Carolina Moreno-López, Federico Rodríguez Cairoli, Rosario Luxardo, Federico Augustovski, Natalia Espinola   +4 more
doaj   +2 more sources

HIV pre-exposure prophylaxis [PDF]

Canadian Medical Association Journal, 2014
Currently, PrEP refers to prophylactic daily oral use of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a formulation that is indicated in Canada for the treatment of HIV infection.
Malika, Sharma, Darrell H S, Tan
openaire   +2 more sources

Knowledge of PEP and PrEP among people living with HIV/aids in Brazil

BMC Public Health, 2021
Background Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) are key to preventing sexual transmission of HIV, whose sexual partners are at high risk of acquiring HIV.
Laelson Rochelle Milanês Sousa, Henrique Ciabotti Elias, Nilo Martinez Fernandes, Elucir Gir, Renata Karina Reis   +4 more
doaj   +1 more source